BEIJING, Nov. 20, 2025 /PRNewswire/ — The central theme of economic and social development during the 15th Five-Year Plan period (2026-30) is to promote high-quality development. Achieving this requires accelerating high-level technological self-reliance and actively fostering new quality productive forces.

As a pivotal force driving the latest wave of scientific and technological revolution and industrial transformation, artificial intelligence (AI) plays a critical role in expediting the emergence of these forces and realizing high-quality socioeconomic growth.

Over the past few years, China has achieved remarkable breakthroughs in key AI domains such as computing infrastructure and AI large models, establishing a leading edge. The nation’s computing capacity ranks second globally, with innovative models like DeepSeek for inference and Ernie’s native multimodal large model earning widespread acclaim. Baidu, for its part, has constructed China’s first cluster comprising 30,000 self-developed P800 Kunlun chips.

To empower high-quality development through AI, a key focus must be on enabling industries to internalize AI capabilities and build native AI strength, transforming them into intrinsic drivers of corporate growth. This not only bolsters the expansion of smart industries but also accelerates the digital upgrading of traditional sectors.

Innovation should be spurred by novel AI applications. Technologies like digital humans, intelligent code agents, and autonomous driving are rigorously validated in real-world scenarios, yielding impressive outcomes. In e-commerce livestreaming and sales support, digital humans serve as highly efficient “digital employees.” Baidu’s Apollo Go robotaxi service, powered by autonomous driving tech, now operates in 22 cities worldwide.

Enterprises can select fitting AI tools, amass exploratory successes, and scale them through experience refinement and replication to hasten progress.

Full integration should be achieved between technological and industrial innovation, and innovation should play a more prominent role in driving development, read the Recommendations of the Central Committee of the Communist Party of China for Formulating the 15th Five-Year Plan (2026-30) for National Economic and Social Development.

“We should build more proof-of-concept and pilot-scale testing platforms, work harder to develop application scenarios and make them more accessible,” according to the Recommendations.

By targeting the pain points such as repetitive tasks, labor shortages, high-risk positions, process bottlenecks, and complex decision-making, AI’s strength in low-cost content creation, automation, intelligent coding, algorithmic optimization and other aspects can help firms cut costs, boost margins, refine decisions, and uncover fresh growth drivers.

Industrial integration should ramp up momentum, strengthening AI as a growth engine. As the world’s sole country encompassing all industrial categories, China holds vast potential for deep AI fusion with the real economy.

Elevating supply chain autonomy in the real economy hinges on superior solutions for production scheduling, resource allocation, route planning, and transaction decisions.

Baidu’s Famou AI agent (described as a commercially available self-evolving agent), dedicated to uncovering optimal solution, has delivered efficiency gains in intricate systems spanning transportation, energy, logistics, and ports. As industries leverage their unique strengths to embed AI capabilities and forge native AI frameworks, the “chemical reactions” from blending general AI models with sector-specific needs will propel social productivity and innovation capability to new heights.

Strategic planning should be reinforced to forge a consensus on “AI empowerment.”

New quality productive forces are defined by innovation – not just in technology and business models, but also in management and institutions. Amid the systemic and structural upheavals from AI and other emerging technologies, exploring human-AI collaborative paradigms for organizations and operations is increasingly urgent.

Seizing the opportunities presented by the digital economy and AI is a must-win imperative for companies. To stay ahead, businesses need to embed AI capability deeply and seamlessly – from strategic decision-making to day-to-day execution, from customer experience to the entire supply chain – permeating every facet of production, operations, and services.

By claiming “intelligent high ground” in their domains, firms can integrate into the broader tide of AI-driven scientific breakthroughs, industrial growth, and application empowerment. This will enable smarter reconfiguration of production factors, faster conversion of innovations into tangible productivity, and a full unleashing of the society’s creative potential.

As one of China’s earliest and most comprehensive investors in AI, Baidu bears the responsibility, capability, and confidence to lead this transformation. We will ramp up investments to build world-class intelligent infrastructure, pioneer cutting-edge large model technologies, and cultivate an open industrial ecosystem, helping industries internalize AI capabilities, cultivate AI native capabilities, and speed up intelligent shifts. In doing so, we aim to contribute anew to China’s high-quality economic development.

SHENZHEN, China, Nov. 20, 2025 /PRNewswire/ — MicroCloud Hologram Inc. (NASDAQ: HOLO), (“HOLO” or the “Company”), a technology service provider, innovatively proposed the “quantum degree” concept, establishing a brand-new theoretical framework for the research on synchronization characteristics of quantum systems. This technology, by introducing the concept of quantum degree in quantum synchronization, precisely measures the synchronized quantum properties in quantum systems.

In terms of theoretical foundation, HOLO’s research is established on a deep understanding of the essential characteristics of quantum systems. The essential difference between quantum systems and classical systems lies in their unique quantum characteristics, including phenomena such as quantum superposition and quantum entanglement. These characteristics make traditional synchronization theory face severe challenges in the quantum domain. The technical framework proposed by HOLO is based on the theoretical foundation of quantum information technology, using the number of synchronized non-commuting observables as the measurement standard for quantumness. This innovative approach breaks through the limitations of classical synchronization theory and establishes a synchronization evaluation system specifically applicable to quantum systems. This theoretical framework not only maintains compatibility with existing synchronization measurement methods but, more importantly, can accurately capture the unique physical properties of quantum systems, providing a reliable theoretical tool for in-depth research on quantum synchronization phenomena.

From the perspective of technical implementation steps, HOLO’s research demonstrates a complete implementation plan. First, HOLO selects a quantum system composed of two weakly interacting cavity qubit systems as the experimental platform, with these systems coupled through boson excitation exchange between cavities. This experimental design ensures the controllability and observability of the quantum system. Second, in the specific operation process, HOLO focuses on the synchronization characteristics of Pauli operator expectation values, verifying the effectiveness and reliability of the quantum degree through precise measurements and data analysis.

At the technical application level, the quantum degree concept proposed by HOLO demonstrates broad application prospects. This technology can be applied to multiple fields such as synchronization control in quantum computers, precision enhancement in quantum sensors, and performance optimization in quantum communication systems. Particularly in superconducting quantum circuit systems, the accurate measurement of quantum degree provides a new technical path for the synchronization control of qubits. With the continuous development of quantum technology, the measurement precision and application scope of quantum degree will further expand. HOLO’s this research achievement provides important technical support for the innovative development of quantum information processing technology, and is expected to play a key role in future quantum technology applications.

About MicroCloud Hologram Inc.

MicroCloud Hologram Inc. (NASDAQ: HOLO) is committed to the research and development and application of holographic technology. Its holographic technology services include holographic light detection and ranging (LiDAR) solutions based on holographic technology, holographic LiDAR point cloud algorithm architecture design, technical holographic imaging solutions, holographic LiDAR sensor chip design, and holographic vehicle intelligent vision technology, providing services to customers offering holographic advanced driving assistance systems (ADAS). MicroCloud Hologram Inc. provides holographic technology services to global customers. MicroCloud Hologram Inc. also provides holographic digital twin technology services and owns proprietary holographic digital twin technology resource libraries. Its holographic digital twin technology resource library utilizes a combination of holographic digital twin software, digital content, space data-driven data science, holographic digital cloud algorithms, and holographic 3D capture technology to capture shapes and objects in 3D holographic form. MicroCloud Hologram Inc. focuses on developments such as quantum computing and quantum holography, with cash reserves exceeding 3 billion RMB, and plans to invest more than 400 million in USD from the cash reserves to engage in blockchain development, quantum computing technology development, quantum holography technology development, and derivatives and technology development in frontier technology fields such as artificial intelligence AR. MicroCloud Hologram Inc.’s goal is to become a global leading quantum holography and quantum computing technology company.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic; financial condition and results of operations; the expected growth of the holographic industry and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission (“SEC”), including the Company’s most recently filed Annual Report on Form 10-K and current report on Form 6-K and its subsequent filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

BRISBANE, Calif., Nov. 20, 2025 /PRNewswire/ — ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a $4.6M grant from the California Institute for Regenerative Medicine (CIRM), and has recently reached a key program milestone, having identified a lead compound that meets key development criteria. This funding will further support the advancement of ReviR Therapeutics’ HTT-PMS1 genetic medicine program, whereby a small molecule selectively reduces the mRNA of two genes implicated in both the cause and progression of Huntington’s disease (HD). ReviR’s novel VoyageR technology platform and scientific approach signify a potential paradigm shift in the treatment of neurodegenerative diseases, providing a more accessible treatment option. The development of this therapeutic asset will pave the way for similar therapies targeting other genetic disorders.

The CIRM grant is awarded through a competitive peer-review process, highlighting the strength of ReviR Therapeutics’ research and its potential impact on Huntington’s disease. The funding will support the development of a transformative therapy that employs a dual-mechanism approach to combat HD by targeting both mutant huntingtin protein (mHTT) and the protein mismatch repair enzyme PMS1. By selectively degrading the mRNA of two of the most critical drivers of Huntington’s pathology, the therapy not only reduces the toxic protein aggregates associated with the disease but also curtails the somatic CAG repeat expansion in HD patients, potentially altering the long-term course of the disease. The CIRM grant will enable ReviR Therapeutics to further develop their preclinical candidate through rigorous preclinical studies and into clinical trials, with an initial goal to ensure that the therapy is both effective in reducing disease progression and amenable to routine clinical use.

Huntington’s disease is a neurodegenerative disorder caused by an abnormal expansion of CAG trinucleotide repeats in the huntingtin (HTT) gene. Individuals with HD have more than 36 CAG repeats in the HTT gene, resulting in the production of mutant huntingtin protein, which leads to the synthesis of mutant huntingtin protein (mHTT) with an expanded polyglutamine tract. This aberrant protein undergoes misfolding and aggregation within neurons, disrupting various cellular functions. Recent research has revealed^[1] that while the CAG length is fixed at birth, the repeats can further expand over time within certain brain cells. Once these expansions exceed a critical threshold (~150 CAG repeats), they cause neuronal death, leading to the development of HD symptoms. 

Paul R. August, PhD, Chief Scientific Officer at ReviR Therapeutics, commented on the grant’s significance: “This CIRM grant is a cornerstone for our targeted approach in treating Huntington’s disease. By leveraging our proprietary RNA-targeting technology and our platform VoyageR, this molecule is poised to revolutionize how we treat HD – offering not just symptomatic relief but a potential disease-modifying therapy, filling an unmet medical need. The ability to deliver this therapy orally would mark a significant breakthrough, enhancing HD patient compliance and quality of life.”

“We are grateful to CIRM for validating our scientific approach and funding the development of this life-changing therapy for HD patients and other neurodegenerative diseases,” said Peng Yue, PhD, co-founder and CEO of ReviR Therapeutics. “This grant will help us advance our dual HTT-PMS1 program toward clinical trials, potentially transforming the treatment landscape for Huntington’s disease patients.” 

About ReviR Therapeutics

ReviR Therapeutics is a global biotechnology company committed to discovering and developing innovative therapies for patients with serious neurogenetic diseases worldwide. ReviR was founded in 2021 by leaders in computational biology, RNA biology, and drug discovery, with the aim to create disease-modifying therapies that are highly specific, efficacious, and safe. ReviR’s lead candidate, RTX-117, is an investigational small molecule therapy for neurogenetic diseases including Charcot-Marie-Tooth disease (CMT). In addition, ReviR’s pipeline includes other orally administered small molecules designed to modulate RNA function. For more information about ReviR Therapeutics, visit www.revirtx.com.

About CIRM

CIRM was created by the people of California to fund stem cell and gene therapy research with the goal of accelerating treatments for patients with unmet medical needs. With $5.5 billion in funding allocated through both Proposition 71 in 2004 and Proposition 14 in 2020, CIRM supports stem cell and gene therapy discoveries from inception through clinical trials, trains a workforce in California to fill jobs in the state’s thriving biotech and biomedical research industry, and creates infrastructure to make clinical trials accessible for people throughout California. All of CIRM’s research, workforce development, and infrastructure programs are designed to benefit the people of California, whose vision created the agency. For more information, visit www.cirm.ca.gov.